Search

In order to elaborate diagnostic and therapeutic recommendations regarding the management of cancer patients with pain, a narrative review of the literature in PubMed and Cochrane database was conducted for the period of 2000-2022. An Expert Group of three scientific associations: Polish Association of Palliative Care, Polish Association for the Study of Pain, and Polish Association of Clinical Oncology was appointed, which made a literature review and formulated guidelines with strength of recommendations and quality of evidence. To achieve optimal effect of pain treatment cancer patients require complex clinical assessment of pain with detailed recognition of pathophysiology, intensity and time frame (baseline and breakthrough -- episodic) of pain. Pain evaluation should encompass other symptoms, comorbidities, disturbances in psychological, social, and spiritual dimensions, which may induce patients' suffering and total pain appearance. An important role plays anticancer local and systemic treatment, which may induce or exacerbate pain induced by cancer or comorbidities. A standard approach in patients with chronic pain in the course of cancer and other diseases is based on World Health Organization (WHO) analgesic ladder algorithm, which is supplemented with non-pharmacological management. It is recommended an individual approach in pain treatment depending on clinical situation of a concrete patient. Efforts should be made to effectively manage other symptoms, which accompany cancer. An introduction of specific treatment taking into account given pathophysiology, time frame and intensity of pain increase effectiveness and significantly shorten time necessary to achieve effective analgesia, and moreover contribute to decrease intensity and frequency of adverse effects of analgesics used. [ABSTRACT FROM AUTHOR]

Nonsteroidal anti-inflammatory drugs (NSAIDs) show high efficacy in anti-inflammatory and analgesic therapy and are the most widely used drugs worldwide. In addition to their efficacy, the widespread use of NSAIDs has been fostered by their wide availability, especially as some are available without a prescription. Unfortunately, this group of drugs is also fraught with adverse effects, including serious ones. Due to the widespread use of NSAIDs, updated data on this group of drugs is critical for practitioners to make the right therapeutic decisions. Each patient requires individualised therapy because, in the case of NSAIDs, the choice of a specific drug, in relation to the type and nature of pain and potential adverse effects, is very important. Over the years, attempts have been made to develop an algorithm for the selection of NSAIDs according to the risk of developing complications associated with drugs of this group in individual cases, taking into account the so-called, golden mean' of NSAIDs and the knowledge of interactions between some NSAIDs and cardioprotective acetylsalicylic acid. This study is another attempt to summarise this issue. With the current state of knowledge, resulting primarily from the publication of the large PRECISION study, which is limited to only three molecules, there remains the fundamental question of expanding the knowledge to include such commonly used drugs as diclofenac, ketoprofen, meloxicam and etoricoxib. In addition to the results of the PRECISION study, this version includes a study by an expert group on other NSAIDs on the Polish market and presents an algorithm for selecting NSAIDs according to individual gastroenterological and cardiovascular risk. [ABSTRACT FROM AUTHOR]

Copyright of Paediatrics & Family Medicine / Pediatria i Medycyna Rodzinna is the property of Medical Communications Sp. z o.o. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The use of club drugs (CDs) is particularly widespread at parties, concerts in dance clubs and nightclubs. Unfortunately, CD is often taken by people who co-occur with other diseases and therefore take pharmacotherapy that may induce unfavorable interactions with CD, which not only changes the picture of complications but also increases the risk erf the severity of complications that may occur in practice, both in emergency medical services, but the consequences of CD use are also visible in hospital wards. The workpresents significant complications resulting from practice, which are a consequence not only of the use erf club drugs, but also of combining CD with other drugs and psychoactive substances in order to potentiate their effects. [ABSTRACT FROM AUTHOR]

Copyright of Pain Research / Ból is the property of Index Copernicus International and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Pain Research / Ból is the property of Index Copernicus International and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Paediatrics & Family Medicine / Pediatria i Medycyna Rodzinna is the property of Medical Communications Sp. z o.o. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Chemsex is defined as the use of certain psychoactive substances in a sexual context by bisexuals, homosexuals and men having sex with men (MSM) as well as transgender people. Chemsex is a relatively new phenomenon in Poland. In Poland, in terms of chemsex as well as the consequences associated with it, the dominant substances are mephedrone, hydroxybutyric acid/ butyrolactone (GHB/GBL) and methamphetamine. In article, we described the dangers arising mainly from the association of various psychoactive substances used in chemsex as well as interactions resulting from their concomitant use with drugs. [ABSTRACT FROM AUTHOR]

Adverse drug reactions are still a growing practical problem in pharmacotherapy. Adverse drug reactions may occur during treatment in the intensive care unit (ICU) or result in admission to the ICU, and in the latter case, pharmacotherapy should always be modified if it is a source of complications. From a practical point of view, observations from Polish ICUs indicate that the use of fluoroquinolone chemotherapeutics is not always rational. Fluoroquinolones are broad-spectrum antibacterials, also with good oral bioavailability and optimal distribution parameters. Their indications in the ICU include the treatment of urinary tract infections, pneumonia, gastrointestinal infections, and infections of the skin, subcutaneous tissue and joints. Fluoroquinolones may cause side effects with a different clinical picture, which in most cases are predictable and active prevention. The paper discusses important from the practical point of view complications that may occur during the use of fluoroquinolones. [ABSTRACT FROM AUTHOR]

Copyright of Pain Research / Ból is the property of Index Copernicus International and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of General Practitioner / Lekarz POZ is the property of Termedia Publishing House and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)